Post-earnings recap
Reported
Tue, Nov 1, 2011
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
88%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Amicus Therapeutics reported a wider-than-expected loss per share, which was better than some analysts anticipated. However, the lack of revenue details and guidance led to a negative stock reaction, with shares dropping 6.69%. Investors may be concerned about the company's future performance and its ability to generate revenue.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.28 | N/A | +15.92% |
| Revenue | N/A | N/A | N/A |
Management expressed a cautious outlook without offering specific future guidance. They emphasized their commitment to advancing their pipeline.
Management did not provide specific guidance for future quarters.
The company is focusing on ongoing clinical trials and product development.